Healthcare
Live Price
Offline$63.32
+0.76% today
1Y Change
-13.02%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
U.S. Physical Therapy, Inc. (USPH) is a Healthcare stock with a market cap of $1.09B and listed on NYSE. The stock last traded around $63.32 and down 13.0% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +16.3%, EPS growth of -22.8%, a dividend yield of 2.5%. What stands out right now is revenue +16.3%, EPS -22.8%, free cash flow -7.2% with operating margin 13.4% and ROIC 6.1%. The dividend matters to the case here, with a current yield around 2.5%. Valuation already assumes a fairly strong business story at P/E 70.7 and price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines USPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
USPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
USPH Max Drawdown
-36.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for USPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$495.0M
-10.5% YoY
FY Net Income
$27.8M
-1.6% YoY
Free Cash Flow
$68.2M
+35.6% YoY
Revenue Growth
+16.3%
EPS Growth
-22.8%
Gross Margin
22.2%
Net Margin
2.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 781M | 671M | 605M | 553M | 495M |
| Gross Profit | 157M | 124M | 122M | 112M | 117M |
| Operating Income | 80M | 63M | 52M | 57M | 71M |
| EBITDA | 110M | 87M | 74M | 76M | 86M |
| Net Income | 15M | 26M | 15M | 28M | 28M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36M | 41M | 153M | 32M | 29M |
| Total Assets | 1.2B | 1.2B | 997M | 858M | 749M |
| Total Liabilities | 434M | 408M | 345M | 374M | 297M |
| Shareholder Equity | 476M | 489M | 476M | 316M | 296M |
| Total Debt | 426M | 295M | 259M | 295M | 223M |
| Net Debt | 390M | 254M | 106M | 264M | 195M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
76M
+30.5% YoY
Capital Expenditures
8M
+0.6% YoY
Free Cash Flow
68M
+35.6% YoY
Key ratios
Gross Margin
22.2%
Operating Margin
13.4%
Net Margin
2.3%
ROE
3.1%
Debt / Equity
0.89x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.